Proteomics in Parkinsons disease: Current trends, translational snags and future possibilities

Expert Review of Proteomics

Volumn 7, Issue 1, 2010, Pages 127-139

  Srivastava, Garima ^a   Singh, Kavita ^a   Tiwari, Manindra Nath ^a   Singh, Mahendra Pratap ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

2D PAGE; Biomarker; Neuroproteome; Parkinsons disease; Proteomics

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALPHA SYNUCLEIN; ALPHA2 INTEGRIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; BETA GLOBIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; DJ 1 PROTEIN; GLOBIN; HAPTOGLOBIN; HEAT SHOCK PROTEIN 70; HEMOGLOBIN BETA CHAIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NEUREXIN; OREXIN; OXIDOPAMINE; PREALBUMIN; PROTEIN KINASE C; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D BINDING PROTEIN; NERVE PROTEIN;

BRAIN; CEREBROSPINAL FLUID; DNA FINGERPRINTING; EARLY DIAGNOSIS; ELECTRON TRANSPORT; ENERGY METABOLISM; GENOME; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR DYNAMICS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PROTEIN ASSEMBLY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEOMICS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; TWO DIMENSIONAL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANIMAL; METHODOLOGY;

ANIMALIA;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PROTEOMICS;

EID: 77951648520     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.09.91     Document Type: Review

References (103)

1. Singh MP, Patel S, Dikshit M, Gupta YK. Contribution of genomics and proteomics in understanding the role of modifying factors in Parkinson's disease. Indian J. Biochem. Biophys. 43(2), 69-81 (2006).
2. Parkinson J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 14(2), 223-236 (2002).
3. Singh S, Dikshit M. Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Brain Res. Rev. 54(2), 233-250 (2007).
4. Caronti G, Antonini C, Calderaro S et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J. Neural. Transm. 108, 803-807(2001).
5. Lubec G, Krapfenbauer K, Fountoulakis M. Proteomics in brain research: potentials and limitations. Prog. Neurobiol. 69(3), 193-211(2003).
6. Kim S, Jeon BS, Heo C et al. a-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. FASEB J. 18(13), 1615-1617 (2004).
7. Licker V, Kövari E, Hochstrasser DF, Burkhard PR. Proteomics in human Parkinson's disease research. J. Proteomics 73(1), 10-29 (2009).
8. Sowell RA, Owen JB, Butterfeld DA. Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res. Rev. 8(1), 1-17 (2009)
9. Fasano M, Lopiano L. a-synuclein and Parkinson's disease: a proteomic view. Expert Rev. Proteomics 5(2), 239-248 (2008).
10. Pienaar IS, Daniels WM, Götz J. Neuroproteomics as a promising tool in Parkinson's disease research. J. Neural. Transm. 115(10), 1413-1430 (2008).
11. Gasser T. Genomic and proteomic biomarkers for Parkinson disease. Neurology 72(7), S27-S31 (2009).
12. Shi M, Caudle WM, Zhang J. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol. Dis. 35(2), 157-164 (2009).
13. Basso M, Giraudo S, Corpillo D, Bergamasco B, Lopiano L, Fasano M. Proteome analysis of human substantia nigra in Parkinsons disease. Proteomics 4(12), 3943-3952 (2004).
14. Sinha A, Patel S, Shukla R, Singh MP. Blood proteome profling in case controls and Parkinson's disease patients in Indian population. Clin. Chim. Acta 380(1-2), 232-234 (2007).
15. Sinha A, Srivastava N, Singh S et al. Identifcation of differentially displayed proteins in cerebrospinal fuid of Parkinson's disease patients: a proteomic approach. Clin. Chim. Acta 400(1-2), 14-20 (2009).
16. Patel S, Sinha A, Singh MP. Identifcation of differentially expressed proteins in striatum of maneb-and paraquat-induced Parkinson's disease phenotype in mouse. Neurotoxicol. Teratol. 29(5), 578-585 (2007).
17. Leighton JK. Application of emerging technologies in toxicology and safety assessment: regulatory perspectives. Int. J. Toxicol. 24(3), 153-155 (2005).
18. Hynd MR, Lewohl JM, Scott HL, Dodd PR. Biochemical and molecular studies using human autopsy brain tissue. J. Neurochem. 85(3), 543-562 (2003).
19. Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain 127(8), 1693-1705 (2004).
20. Mitchell A, Brindle N. CSF phosphorylated tau-does it constitute an accurate biological test for Alzheimer's disease? Int. J. Geriatr. Psychiatry 18(5), 407-411 (2003).
21. Hodgetts A, Levin M, Kroll JS, Langford PR. Biomarker discovery in infectious diseases using SELDI. Future Microbiol. 2(1), 35-49 (2007).
22. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1(9), 683-695 (2002).
23. Graeber MB. Biomarkers for Parkinson's disease. Exp. Neurol. 216(2), 249-253 (2009).
24. Fasano M, Alberio T, Lopiano L. Peripheral biomarkers of Parkinson's disease as early reporters of central neuro degeneration. Biomarker Med. 2(5), 465-478 (2008).
25. Antoniades CA, Barker RA. The search for biomarkers in Parkinson's disease: a critical review. Expert Rev. Neurother. 8(12), 1841-1852 (2008).
26. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF 3rd, Liotta LA. CSF proteome: a protein repository for potential biomarker identifcation. Expert Rev. Proteomics 2(1), 57-70 (2005).
27. Waragai M, Wei J, Fujita M et al. Increased level of DJ-1 in the cerebrospinal fuids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345(3), 967-972 (2006).
28. Zhang Y, Dang C, Ma Q, Shimahara Y. Expression of nerve growth factor receptors and their prognostic value in human pancreatic cancer. Oncol. Rep. 14(1), 161-171(2005).
29. Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profle distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129(4), 526-529 (2008).
30. El-Agnaf OM, Salem SA, Paleologou KE et al. Detection of oligomeric forms of a-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20(3), 419-425 (2006).
31. Pan S, Rush J, Peskind ER et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fuid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-fight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J. Proteome Res. 7(2), 720-730 (2008).
32. Sheta EA, Appel SH, Goldknopf IL. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Rev. Proteomics 3(1), 45-62 (2006).
33. Goldknopf IL, Sheta EA, Bryson J et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem. Biophys. Res. Commun. 342(4), 1034-1039 (2006).
34. Kikuchi A, Takeda A, Onodera H et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis. 9(2), 244-248 (2002).
35. Yasuhara T, Hara K, Sethi KD, Morgan JC, Borlongan CV. Increased 8-OHdG levels in the urine, serum and substantia nigra of hemiparkinsonian rats. Brain Res. 1133(1), 49-52 (2007).
36. Ilic T V, Jovanovic M, Jovicic A, Tomovic M. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct. Neurol. 4(3), 141-147 (1999)
37. Drouot X, Moutereau S, Nguyen JP et al Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61(4), 540-543 (2003).
38. Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers 21 (2), 93-101 (2005).
39. Nagatsu T, Sawada M. Infammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des. 11(8), 999-1016 (2005).
40. Mila S, Albo AG, Corpillo D et al Lymphocyte proteomics of Parkinson's disease patients reveals cytoskeletal protein dysregulation and oxidative stress Biomarker Med. 3(2), 117-128 (2009).
41. Wikoff WR, Pendyala G, Siuzdak G, Fox HS. Metabolomic analysis of the cerebrospinal fuid reveals changes in phospholipase expression in the CNS of SIV-infected macaques. J. Clin. Invest. 118(7), 2661-2669 (2008).
42. Cairns DA, Barrett JH, Billingham LJ et al. Sample size determination in clinical proteomic profling experiments using mass spectrometry for class comparison. Proteomics 9(1), 74-86 (2009).
43. Wu Q, Maniatis T. A striking organization of a large family of human neural cadherin-like cell adhesion genes. Cell 97(6), 779-790 (1999).
44. Tribl F, Marcus K, Meyer HE, Bringmann G, Gerlach M, Riederer P. Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle. J. Neural. Transm. 113(6), 741-749 (2006).
45. Butterfeld DA, Castegna A. Proteomics for the identifcation of specifcally oxidized proteins in brain: technology and application to the study of neurodegenerative disorders. Amino Acids 25(3-4), 419-425 (2003).
46. Werner CJ, Heyny-von Haussen R, Mall G, Wolf S. Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci. 6, 8 (2008).
47. Patt S, Gertz HJ, Gerhard L, Cervós-Navarro J. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study. Histol Histopathol. 6(3), 373-380 (1991).
48. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS. 3, 4-dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res. 989(2), 205-213 (2003).
49. Tobin JE, Cui J, Wilk JB et al. Sepiapterin reductase expression is increased in Parkinson s disease brain tissue. Brain Res. 1139, 42-47 (2007).
50. Fasano M, Bergamasco B, Lopiano L. Is neuromelanin changed in Parkinsons disease? Investigations by magnetic spectroscopies. J. Neural. Transm. 113(6), 769-774 (2006).
51. Grimm J, Mueller A, Hefti F, Rosenthal A. Molecular basis for catecholaminergic neuron diversity. Proc. Natl Acad. Sci. USA 101(38), 13891-13896 (2004).
52. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587), 979-980 (1983).
53. Patel S, Singh K, Singh S, Singh MP. Gene expression profles of mouse striatum in control and maneb + paraquat-induced Parkinsons disease phenotype: validation of differentially expressed energy metabolizing transcripts. Mol. Biotechnol 40(1), 59-68 (2008).
54. Thiruchelvam M, Richfeld EK, Goodman BM, Baggs RB, Cory-Slechta DA. Developmental exposure to the pesticides paraquat and maneb and the Parkinsons disease phenotype. Neurotoxicology 23(4-5), 621-633 (2002).
55. Liu J, Zhou Y, Wang Y, Fong H, Murray TM, Zhang J. Identifcation of proteins involved in microglial endocytosis of a-synuclein. J. Proteome Res. 6(9), 3614-3627 (2007).
56. Przedborski S, Chen Q, Vila M et al. Oxidative post-translational modifcations of a-synuclein in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinsons disease. J. Neurochem. 76(2), 637-640 (2001).
57. Jin J, Meredith GE, Chen L et al Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease. Brain Res. Mol. Brain Res. 134(1), 119-138 (2005).
58. McLaughlin P, Zhou Y, Ma T et al Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity Glia 53(6), 567-582 (2006).
59. Svensson M, Sköld K, Nilsson A, Fälth M, Svenningsson P, Andrén PE. Neuropeptidomics: expanding proteomics downwards. Biochem. Soc. Trans. 35(Pt 3), 588-593 (2007).
60. Ara J, Przedborski S, Naini AB et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc. Natl Acad. Sci. USA 95(13), 7659-7663 (1998).
61. Ungerstedt U. 6-hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5(1), 107-110 (1968).
62. Luthman J, Fredriksson A, Sundström E, Jonsson G, Archer T. Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav. Brain Res. 33(3), 267-277 (1989).
63. Pierson J, Svenningsson P, Caprioli RM, Andren PE. Increased levels of ubiquitin in the 6-OHDA-lesioned striatum of rats. J. Proteome Res. 4(2), 223-226 (2005).
64. Elkon H, Melamed E, Offen D. 6-hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell. Mol. Neurobiol. 21(6), 771-781 (2001).
65. Nakamura M, Yamada M, Ohsawa T et al. Phosphoproteomic profling of human SH-SY5Y neuroblastoma cells during response to 6-hydroxydopamine-induced oxidative stress. Biochim. Biophys. Acta 1763(9), 977-989 (2006).
66. +-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res. 57(1), 86-94 (1999).
67. Lee YM, Park SH, Shin DI et al. Oxidative modifcation of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J. Biol. Chem. 283(15), 9986-9998 (2008).
68. Saito Y, Nishio K, Ogawa Y et al. Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and-independent action. Free Radic. Biol. Med. 42(5), 675-685 (2007).
69. Shen Y, Yu Y, Guo H, Tang Z, Yu FS, Zhou J. Identifcation and comparative analysis of differentially expressed proteins in rat striatum following 6-hydroxydopamine lesions of the nigrostriatal pathway: up-regulation of amyloid precursor-like protein 2 expression. Eur. J. Neurosci. 16(5), 896-906 (2002).
70. Nilsson A, Sköld K, Sjögren B et al. Increased striatal mRNA and protein levels of the immunophilin FKBP-12 in experimental Parkinson's disease and identifcation of FKBP-12-binding proteins. J. Proteome Res. 6(10), 3952-3961 (2007).
71. Lee YM, Park SH, Chung KC, Oh YJ. Proteomic analysis reveals upregulation of calreticulin in murine dopaminergic neuronal cells after treatment with 6-hydroxydopamine. Neurosci. Lett. 352(1), 17-20 (2003).
72. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquat causes up-regulation and aggregation of a-synuclein in mice: paraquat and a-synuclein. J. Biol. Chem. 277(3), 1641-1644 (2002).
73. Miller RL, Sun GY, Sun AY. Cytotoxicity of paraquat in microglial cells: Involvement of PKC-d and ERK1/2-dependent NADPH oxidase. Brain Res. 1167, 129-139 (2007).
74. Höglinger GU, Carrard G, Michel PP et al. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical defcits in a cellular model of Parkinson's disease. J. Neurochem. 86(5), 1297-1307 (2003).
75. Wang XF, Li S, Chou AP, Bronstein JM. Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease. Neurobiol. Dis. 23(1), 198-205 (2006).
76. Casarejos MJ, Menéndez J, Solano RM, Rodríguez-Navarro JA, García de Yébenes J, Mena MA. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem. 97(4), 934-946 (2006).
77. Wang C, Ko HS, Thomas B et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. 14(24), 3885-3897 (2005).
78. Terzioglu M, Galter D. Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J. 275(7), 1384-1391 (2008).
79. Chesselet MF, Fleming S, Mortazavi F, Meurers B. Strengths and limitations of genetic mouse models of Parkinson's disease. Parkinsonism Relat. Disord. 14(2), S84-S87 (2008).
80. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 26(3), 231-243 (1975).
81. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem. 250(10), 4007-4021 (1975).
82. Klose J, Nock C, Herrmann M et al. Genetic analysis of the mouse brain proteome. Nat. Genet. 30(4), 385-393 (2002).
83. Fonteh AN, Harrington RJ, Huhmer AF, Biringer RG, Riggins JN, Harrington MG. Identifcation of disease markers in human cerebrospinal fuid using lipidomic and proteomic methods. Dis. Markers 22(1-2), 39-64 (2006).
84. Morón JA, Devi LA. Use of proteomics for the identifcation of novel drug targets in brain diseases. J. Neurochem. 102(2), 306-315 (2007).
85. Görg A, Weiss W, Dunn MJ. Current 2D electrophoresis technology for proteomics. Proteomics 4(12), 3665-3685 (2004).
86. Garbis S, Lubec G, Fountoulakis M. Limitations of current proteomics technologies. J. Chromatogr. A 1077(1), 1-18 (2005).
87. Fountoulakis M. Proteomics: current technologies and applications in neurological disorders and toxicology. Amino Acids 21(4), 363-381 (2001).
88. Marcus K, Schmidt O, Schaefer H, Hamacher M, van Hall A, Meyer HE. Proteomics-application to the brain. Int. Rev. Neurobiol. 61, 285-311 (2004).
89. Leverenz JB, Umar I, Wang Q et al. Proteomic identifcation of novel proteins in cortical lewy bodies. Brain Pathol. 17(2), 139-145 (2007).
90. Haab BB. Methods and applications of antibody microarrays in cancer research. Proteomics 3(11), 2116-2122 (2003).
91. Davidsson P, Sjögren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis. Markers 21(2), 81-92 (2005).
92. Rite I, Argüelles S, Venero JL et al. Proteomic identifcation of biomarkers in the cerebrospinal fuid in a rat model of nigrostriatal dopaminergic degeneration. J. Neurosci. Res. 85(16), 3607-3618 (2007).
93. Xia Q, Liao L, Cheng D et al. Proteomic identifcation of novel proteins associated with Lewy bodies. Front. Biosci. 13, 3850-3856 (2008).
94. Tribl F, Asan E, Arzberger T et al. Identifcation of L-ferritin in neuromelanin granules of the human substantia nigra-a targeted proteomics approach. Mol. Cell. Proteomics 8(8), 1832-1838 (2009).
95. Jin J, Hulette C, Wang Y et al. Proteomic identifcation of a stress protein, mortalin/mthsp70/GRP75: relevance to Parkinson disease. Mol. Cell. Proteomics 5(7), 1193-1204 (2006).
96. Liu B, Shi Q, Ma S et al. Striatal 19S Rpt6 defcit is related to a-synuclein accumulation in MPTP-treated mice. Biochem. Biophys. Res. Commun. 376(2), 277-282 (2008).
97. Xun Z, Sowell RA, Kaufman TC, Clemmer DE. Quantitative proteomics of a presymptomatic A53T a-synuclein Drosophila model of Parkinson disease. Mol. Cell. Proteomics 7(7), 1191-1203 (2008).
98. Dukes AA, Van Laar VS, Cascio M, Hastings TG. Changes in endoplasmic reticulum stress proteins and aldolase A in cells exposed to dopamine. J. Neurochem. 106(1), 333-346 (2008).
99. Diedrich M, Mao L, Bernreuther C et al. Proteome analysis of ventral midbrain in MPTP-treated normal and L1cam transgenic mice. Proteomics 8(6), 1266-1275 (2008).
100. Zhang L, Chang M, Li H et al. Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. Brain Res. 1153, 196-203 (2007).
101. Xun Z, Sowell RA, Kaufman TC, Clemmer DE. Protein expression in a Drosophila model of Parkinson's disease. J. Proteome Res. 6(1), 348-357 (2007).
102. Sköld K, Svensson M, Nilsson A et al. Decreased striatal levels of PEP-19 following MPTP lesion in the mouse. J. Proteome Res. 5(2), 262-269 (2006).
103. De Iuliis A, Grigoletto J, Recchia A, Giusti P, Arslan P. A proteomic approach in the study of an animal model of Parkinson's disease. Clin. Chim. Acta 357(2), 202-209 (2005).